EL7.AI
Mergers & AcquisitionsMediumUpdated×2•Originally published 15 July 2026•Updated 16 July 2026•
1 min read

Eli Lilly Officially Acquires AtaiBeckley in $2.8 Billion Deal

Portrait of a man behind a pharmaceutical pipeline illustration with a Lilly logo safe and a $2.8B coin.

Key Facts

1Eli Lilly is in talks to acquire psychedelic drugmaker AtaiBeckley, with a deal potentially announced this week.

In a move marking a significant shift in mental health strategy, Eli Lilly has officially announced the acquisition of innovative psychiatric drugmaker AtaiBeckley. The confirmed deal is valued at $2.8 billion, as Eli Lilly aims to integrate psychedelic-based therapies into its neuroscience portfolio. This announcement confirms previous reports of the company's intent to lead this growing medical niche and expand its treatment options for treatment-resistant depression.

This strategic shift comes as the psychiatric drug sector sees renewed interest from Big Pharma, as companies seek to offset traditional patent cliffs. In comparison to peers, Johnson & Johnson previously reported strong results for its Spravato treatment, which has stimulated M&A appetite in the space per market data. AtaiBeckley is considered a leader in clinical research for this class of drugs, making it a strategic target for long-term growth in the healthcare sector.

Regarding market performance, LLY shares closed at $1156.63 (close July 15, 2026), with the stock hitting a session high of $1160.82. Traders are now monitoring operational integration details and the deal's impact on future earnings, while the market awaits the U.S. Monetary Policy Report on July 10, 2026, which could impact investor sentiment across growth and biotech sectors.